Loading...
•
Dec 31, 2020
Incyte Q4 2020 Earnings Report
Incyte reported strong revenue growth, driven by Jakafi demand and the launches of Monjuvi and Pemazyre, while also achieving positive results across multiple late-stage programs.
Key Takeaways
Incyte reported its 2020 fourth quarter and year-end financial results, highlighting strong revenue growth driven by Jakafi and the launches of Monjuvi and Pemazyre. The company also provided 2021 financial guidance and updates on key clinical programs, anticipating regulatory decisions on seven applications and a potential U.S. launch of ruxolitinib cream.
Revenue growth was strong, driven by demand for Jakafi.
Monjuvi and Pemazyre launches continue to gain momentum.
Positive results were announced across multiple late-stage programs.
Seven applications are seeking approval in 2021.
Forward Guidance
Incyte provided its 2021 financial guidance, which includes net product revenue guidance for Jakafi and other Hematology/Oncology products. The guidance does not include revenue from potential new product launches but includes costs to support the potential launches of ruxolitinib cream, pemigatinib, and tafasitamab.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...